A Randomized Factorial Trial of Vitamins C and E and Beta Carotene in the Secondary Prevention of Cardiovascular Events in Women
- 13 August 2007
- journal article
- research article
- Published by American Medical Association (AMA) in Archives of Internal Medicine
- Vol. 167 (15), 1610-8
- https://doi.org/10.1001/archinte.167.15.1610
Abstract
Randomized trials have largely failed to support an effect of antioxidant vitamins on the risk of cardiovascular disease (CVD). Few trials have examined interactions among antioxidants, and, to our knowledge, no previous trial has examined the individual effect of ascorbic acid (vitamin C) on CVD. The Women's Antioxidant Cardiovascular Study tested the effects of ascorbic acid (500 mg/d), vitamin E (600 IU every other day), and beta carotene (50 mg every other day) on the combined outcome of myocardial infarction, stroke, coronary revascularization, or CVD death among 8171 female health professionals at increased risk in a 2 x 2 x 2 factorial design. Participants were 40 years or older with a history of CVD or 3 or more CVD risk factors and were followed up for a mean duration of 9.4 years, from 1995-1996 to 2005. A total of 1450 women experienced 1 or more CVD outcomes. There was no overall effect of ascorbic acid (relative risk [RR], 1.02; 95% CI, 0.92-1.13 [P = .71]), vitamin E (RR, 0.94; 95% CI, 0.85-1.04 [P = .23]), or beta carotene (RR, 1.02; 95% CI, 0.92-1.13 [P = .71]) on the primary combined end point or on the individual secondary outcomes of myocardial infarction, stroke, coronary revascularization, or CVD death. A marginally significant reduction in the primary outcome with active vitamin E was observed among the prespecified subgroup of women with prior CVD (RR, 0.89; 95% CI, 0.79-1.00 [P = .04]; P value for interaction, .07). There were no significant interactions between agents for the primary end point, but those randomized to both active ascorbic acid and vitamin E experienced fewer strokes (P value for interaction, .03). There were no overall effects of ascorbic acid, vitamin E, or beta carotene on cardiovascular events among women at high risk for CVD.Keywords
This publication has 37 references indexed in Scilit:
- Mortality in Randomized Trials of Antioxidant Supplements for Primary and Secondary PreventionJAMA, 2007
- Fruit and Vegetable Consumption and Risk of Coronary Heart Disease: A Meta-Analysis of Cohort StudiesJournal of Nutrition, 2006
- Calcium plus Vitamin D Supplementation and the Risk of FracturesThe New England Journal of Medicine, 2006
- Plasma carotene and α-tocopherol in relation to 10-y all-cause and cause-specific mortality in European elderly: the Survey in Europe on Nutrition and the Elderly, a Concerted Action (SENECA)The American Journal of Clinical Nutrition, 2005
- Failure of Vitamin E in Clinical Trials: Is Gamma-Tocopherol the Answer?Nutrition Reviews, 2005
- Simvastatin and Niacin, Antioxidant Vitamins, or the Combination for the Prevention of Coronary DiseaseThe New England Journal of Medicine, 2001
- Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomised trial in general PracticeThe Lancet, 2001
- Secondary prevention with antioxidants of cardiovascular disease in endstage renal disease (SPACE): randomised placebo-controlled trialThe Lancet, 2000
- Vitamin E Supplementation and Cardiovascular Events in High-Risk PatientsThe New England Journal of Medicine, 2000
- β-Carotene Supplementation and Incidence of Cancer and Cardiovascular Disease: the Women's Health StudyJNCI Journal of the National Cancer Institute, 1999